- ISRIB (trans-isomer)
- GSK2606414
| GSK2656157PERK inhibitor |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
- Purity = 98.82%
- COA (Certificate Of Analysis)
- HPLC
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
Related Biological Data
| Description | GSK2656157 is an ATP-competitive and highly selective inhibitor of PERK with an IC50 value of 0.9 nM. | |||||
| Targets | PERK | |||||
| IC50 | 0.9 nM | |||||
| Cell experiment [1]: | |
Cell lines | HT1080 cells |
Preparation method | The solubility of this compound in DMSO is > 20.8 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reacting condition | 0.1-10 µM, 24 h |
Applications | In HT1080 cells, 0.1 μM GSK2656157 was efficient to block the activity of PERK. Cells treated with GSK2656157 exhibited increasing eIF2α phosphorylation in order to compensating the loss of PERK. |
| Animal experiment [2]: | |
Animal models | Eight- to twelve-week-old naive female CD-1, female nu/nu CD-1 mice and severe combined immunodeficient (SCID) mice |
Dosage form | 50, 150 mg/kg, twice daily |
Application | After a single 50 mg/kg oral dose of GSK2656157, mice occurs inhibited phospho-PERK in the pancreas completely through 8 hours. And the activity of PERK was recovered to almost normal levels at 18 hours. Twice daily administration of 50 or 150 mg/kg GSK2656157 to mice resulted in an inhibition of multiple tumor xenografts growth in a dose-dependent manner. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Krishnamoorthy J, Rajesh K, Mirzajani F, et al. Evidence for eIF2α phosphorylation-independent effects of GSK2656157, a novel catalytic inhibitor of PERK with clinical implications[J]. Cell Cycle, 2014, 13(5): 801-806. [2]. Atkins C, Liu Q, Minthorn E, et al. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity[J]. Cancer research, 2013, 73(6): 1993-2002. | |
GSK2656157 Dilution Calculator
calculate
GSK2656157 Molarity Calculator
calculate
| Cas No. | 1337532-29-2 | SDF | Download SDF |
| Synonyms | N/A | ||
| Chemical Name | 1-(5-(4-amino-7-methyl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)-4-fluoroindolin-1-yl)-2-(6-methylpyridin-2-yl)ethanone | ||
| Canonical SMILES | NC1=NC=NC2=C1C(C3=CC=C4C(CCN4C(CC5=NC(C)=CC=C5)=O)=C3F)=CN2C | ||
| Formula | C23H21FN6O | M.Wt | 416.45 |
| Solubility | ≥20.8225mg/mL in DMSO | Storage | Store at -20°C |
| Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
GSK2656157 is a highly selective inhibitor of protein kinase R-like ER kinase (PERK) with IC50 value of 0.9nM [1].
GSK2656157 is highly selective for PERK enzyme against a panel of 300 kinases. In the BxPC3 pancreatic tumor cell line, treatment of GSK2656157 causes an inhibition of PERK and decreases in the downstream substrates, including phospho-eIF2α, ATF4 and CHOP. The inhibition of PERK results in effects on de novo protein synthesis as shown in BxPC3 cells [1].
In vivo assay shows that a single 50 mg/kg oral dose of GSK2656157 can completely inhibit the Thr980 phosphorylation of endogenous pancreatic PERK in mice. Furthermore, GSK2656157 causes dose-dependent inhibition of tumor growth in human tumor xenograft models of pancreatic cancer (BxPC3, HPAC and Capan2) and multiple myeloma (NCI-H929). Among these cancers, the Capan2 tumor is most sensitive [1].
References:[1] Atkins C, Liu Q, Minthorn E, Zhang SY, Figueroa DJ, Moss K, Stanley TB, Sanders B, Goetz A, Gaul N, Choudhry AE, Alsaid H, Jucker BM, Axten JM, Kumar R. Characterization of a novel PERK kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res. 2013 Mar 15;73(6):1993-2002.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
祝大家元宵节快乐!
我们有个中药项目，需要采用乙酸乙酯萃取，有效成分分布在乙酸乙酯有机层中，现在我们采用旋转蒸发仪回收乙酸乙酯直到蒸发瓶中有效成分成蜂窝固体状才取出，但现在有一个问题，我如何判断蒸发瓶中蜂窝状固体可以刮出？目前我们实验室做的时候是根据蒸发瓶释放真空时蜂窝状固体不收缩的标准作为蒸干取出固体物的，但这个标准太粗放了，我也知道光靠旋转蒸发仪是不可能除尽有机溶剂，我们后续还有一个工艺可以除去蒸干固体残留的有机溶剂。我现在想知道有没有一些判断标准用于旋转蒸发仪固体蒸干可以取出来的标准可供参考啊？盼指教，谢谢
请问有什么方法可以不漏气呢？
谢谢大家！！
已经试过的方法有：电吹风烘箱
将试的方法是：超声
大家有什么好建议，谢谢了！
不知道有多少这样的学生呢,其实我们做学生时也没人特意教,能用旋蒸都是很了不起的，老师不教也会主动学习,偷学或查资料
做实验常规试剂的沸点背不得很糟糕,但背得后问我为什么在旋蒸上蒸乙醇用60度,不用78度,我就吐血了
只好普及知识,借用BUCHI的介绍,这么有名的公司没人知道也是很菜的
羊毛冷凝器
2500年以前，由于巧合，希腊水手在公海上发现了羊毛冷凝器。当时，船只遇难，船员必须从盐水中获得重要的淡水。为此，他们将海水加热，并利用固定在罐子上方的羊毛将蒸汽冷凝。这种名为“羊毛冷凝器”的东西从古代广泛传播到现代，与较早的“瓷碗变体”比较，代表了一种巨大的进步。
羊毛冷凝器.JPG(6.82k)
一背景：最近正用水饱和正丁醇萃取某海洋生物乙醇提取物，考虑活性问题，温度一般不超过56度。
二问题：萃取液在开始蒸发效果还好，但超过一个钟后慢下来，最后几乎不滴。很多高手提到再40度就可以蒸发，不到五十度就可以蒸去大部。我们定在五十几度也一样，慢慢发现停机休息几个小时又可以蒸发了，但过段时间又慢下来，百思不得解。
三折腾：于是开始试验水饱和正丁醇的制备是否有问题、蒸发效果跟时间及水浴温度的关系、蒸发剩余加水多少。。。。毫无进展，郁闷，有时这机器休息时间短些还不行，真想烧香拜佛了。
四辛勤加运气：一日，感觉水泵水箱水温有点高（没有象汽车那样弄水循环，一般干些就加满），担心电动机烧坏于是换凉水，突然发现冷凝管液滴增多，下滴速度加快了，终于找到原因：水泵抽吸出问题了！可能是工作时间长了，水泵电动机发热，如果温度升高，抽吸效果下降。虽然仪器指示负压很高了，其实没有起到很大作用，比如关掉水泵，只要不开气阀负压也不会降下来的。
五解决：马上使用循环水降低水箱温度。问题解决，但新的问题来了：进出水速度一致难调而且靠近水箱上缘、感觉效果不好。素性将冷凝水直接加入水箱，又省水又达到目的：可是水的多少不好控制。解决：直接把水泵水箱置于水池中（支架上）。
五思考：1实验中首先要对仪器的使用性能有所了解。后仔细观察，其实此水泵是可以进出水的（循环），只是按一般的使用习惯没有使用循环水，而只是动手添加水。奉劝各实验室水泵改循环水，特别是需要较长时间运作时，（形式多样，保证水泵长时间工作就好），而不是添加水，否则，使用时间长了会跟我们一样郁闷折腾。
2现象的存在总是有原因、可以解释的。多观察、多动手、多对比各种差异有助于找到某种原因。
3不要过分相信仪器显示的数据：起码这回我们被骗了：负压显示那么高，一直不怀疑水泵抽吸的效果；从这启发：另一同志仔细测水浴锅的温度，发现居然相差二、三度左右！二、三度对提取海洋生物药来讲简直是“差之毫厘，谬以千里”！
最后多谢捧场！呵呵
